Biotech Stock Mailbag: Bristol, Exelixis, Lion Bio, GW Pharma
at The Street - Fri Sep 18, 5:11AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
GWPH: 87.75 (+0.45), ICPT: 181.90 (-8.81), LBIO: 6.48 (+0.03), RMTI: 8.99 (+0.78), BMY: 61.44 (+0.93), KERX: 4.25 (+0.23), NVS: 91.90 (-0.71), EXEL: 5.99 (+0.14)
Global Insulin Resistance Pipeline Review 2015 - 9 Companies & 19 Drug Profiles
M2 - Tue Sep 08, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z47c8s/insulin) has announced the addition of the "Insulin Resistance - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Insulin Resistance, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insulin Resistance and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AUS Bio Limited - Genfit SA - GlaxoSmithKline Plc - Hadasit Medical Research Services & Development Ltd - Mertiva AB - Mochida Pharmaceutical Co., Ltd. - Novartis AG - Prometheon Pharma, LLC - Sanofi Drug Profiles - 6860766 - BVS-857 - Drugs to Agonize GABA Receptor for Diabetes and Rheumatoid Arthritis - Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - elafibranor - englerin A - MD-960 - Oligonucleotide to Inhibit IRAK-3 for Cardiovascular and Metabolic Disorders - PEG-Catalase - Peptide for Obesity and Insulin Resistance - SAR-088 - SERX-1 - Small Molecule for Hypertension and Insulin Resistance - Small Molecule to Antagonize TRPV4 for Metabolic Disorders and Inflammation - Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Small Molecule to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular - Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance For more information visit http://www.researchandmarkets.com/research/z47c8s/insulin
GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)
Abdominal Obesity - Pipeline Review, H1 2015
M2 - Fri Aug 14, 5:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d8pj62/abdominal_obesity) has announced the addition of the "Abdominal Obesity - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Abdominal obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Abdominal obesity and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons To Buy The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aileron Therapeutics - Genfit - Neothetics - Zafgen For more information visit http://www.researchandmarkets.com/research/d8...al_obesity
Non-Alcoholic Steatohepatitis Clinical Trials Review, H1, 2015
M2 - Tue Aug 04, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ks9fl3/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015" report to their offering. Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2015 provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Genextra S.p.a. - Genfit SA - Cempra, Inc. - Raptor Pharmaceuticals Corp. - Nimbus Therapeutics, LLC - Immuron Limited - Gilead Sciences, Inc. - Galmed International Ltd. - Galectin Therapeutics, Inc. - DURECT Corporation Clinical Trial Overview of Top Institutes / Government - The National Institute of Diabetes and Digestive and Kidney Diseases - Tehran University of Medical Sciences - University of California, San Diego - National Nutrition and Food Technology Research Institute - Yokohama City University - Bambino Gesu Hospital and Research Institute - Ghent University Hospital - Gunma Liver Study Group - Hadassah Medical Organization - Hiroshima University Hospital For more information visit http://www.researchandmarkets.com/research/ks...nalcoholic
RPTP: 5.99 (+0.10), GILD: 100.65 (-0.16), GALT: 2.61 (-0.10), DRRX: 2.13 (+0.02), CEMP: 29.31 (+0.29)
Nonalcoholic steatohepatitis (NASH) - 2015 Pipeline Analysis
M2 - Tue Jul 21, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kf56cl/nonalcoholic) has announced the addition of the "Nonalcoholic steatohepatitis (NASH) - Pipeline Analysis" report to their offering. This report gives comprehensive insight on the various drugs being developed for the treatment of NASH. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins and RNA-based therapeutics, but excludes Off-label, symptom relief drugs, generic combinations. The report also covers hot targets in research for NASH treatments and disease progression biomarkers. This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space. NASH is associated with fatty liver, hepatic inflammation, hepatocyte injury and fibrogenesis and may worsen into fibrosis or cirrhosis, liver failure and rarely into liver cancer. Currently, there are no approved drugs for NASH by U.S. Food and Drug Administration (FDA) and there a high unmet clinical need. NASH, if untreated can progress to liver-destroying cirrhosis and potentially cancer. Majority of the NASH pipeline drugs are from specialised small to mid pharmaceutical & biotech companies. As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead's acquisition of Phenex FXR program & Boehringer's acquisition of NASH clinical asset from Pharmaxis supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH. There is a tremendous opportunity for upcoming therapies specific to NASH such as MAbs, RNA-based therapies & Recombinant proteins. These modalities may provide Anti-fibrosis, Anti-inflammatory and metabolic benefits. Key Topics Covered: 1. Report Description 2. Introduction 3. Hot Targets, Mechanisms & Therapies 4. Market Data 5. Pipeline Analysis 6. Small Molecules 7. Large Molecule 8. RNA-based Therapy 9. Recombinant Proteins 10. Antibodies 11. Large Molecules (Unspecified) 12. Other Molecules 13. NASH Drug Analysis based on Mechanisms 14. Major Players - Boehringer Ingelheim - Cerenis Therapeutics - Connexios Life Sciences - Genfit - Gilead Sciences - Intercept - Islet Sciences - Nimbus Therapeutics - Verva Pharmaceuticals - Viking Therapeutics For more information visit http://www.researchandmarkets.com/research/kf...nalcoholic
GILD: 100.65 (-0.16), VKTX: 6.50 (-0.30)
Galectin initiates enrollment in mid-stage trial of GR-MD-02 in NASH
Seeking Alpha - at Seeking Alpha - Wed Jul 01, 10:30AM CDT
MNOV: 2.82 (-0.03), GLMD: 9.01 (+0.12), LJPC: 24.50 (+0.76), CNAT: 4.21 (-0.06), GALT: 2.61 (-0.10), RGLS: 6.86 (+0.29), DRRX: 2.13 (+0.02), RPTP: 5.99 (+0.10), GILD: 100.65 (-0.16), SHPG: 200.90 (-1.85), MRK: 50.95 (-0.07), AZN: 32.23 (-0.16), ICPT: 181.90 (-8.81), VBLT: 7.35 (-0.23), TBRA: 10.56 (-0.63)
Betting On The First NASH Blockbuster Drug: Dump Intercept And Buy Genfit
Logribel Biostocks - at Seeking Alpha - Fri Jun 19, 11:37AM CDT
ICPT: 181.90 (-8.81)
Liver Fibrosis - Pipeline Review, H1 2015 - Featuring 23 Therapeutics Companies
M2 - Thu Jun 11, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7lgbpl/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advinus Therapeutics Ltd. - Angion Biomedica Corp. - BerGenBio AS - BiOrion Technologies B.V. - Celgene Corporation - Digna Biotech, S.L. - FibroGen, Inc. - Galectin Therapeutics, Inc. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - GNI Group Ltd. - La Jolla Pharmaceutical Company - LG Life Sciences, Ltd. - Nitto Denko Corporation - Pharmaxis Limited - Promedior, Inc. - Promethera Biosciences S.A. - ProMetic Life Sciences Inc. - RXi Pharmaceuticals Corporation - TCM Biotech International Corp - Vascular Biogenics Ltd. - Virobay Inc. For more information visit http://www.researchandmarkets.com/research/7l...r_fibrosis
GILD: 100.65 (-0.16), GALT: 2.61 (-0.10), FGEN: 21.77 (+0.22), VBAY: (), VBLT: 7.35 (-0.23), CELGZ: 1.74 (+0.04)
The Math Could Get Weird, But Intercept Pharmaceuticals Looks Too Cheap
Stephen Simpson, CFA - at Seeking Alpha - Thu May 21, 7:24AM CDT
GILD: 100.65 (-0.16), CNAT: 4.21 (-0.06), ICPT: 181.90 (-8.81)
Genfit: Why Intercept's NASH Phase 3 Design Is Good News For Genfit
Logribel Biostocks - at Seeking Alpha - Wed May 20, 7:56AM CDT
ICPT: 181.90 (-8.81)
Bluebird Bio, Intercept Pharma Reach Accords on Pivotal Trial Designs
at The Street - Tue May 19, 10:02AM CDT
Bluebird Bio and Intercept Pharma have reached separate agreements with regulators on the designs of key clinical trials for their respective blood disorder and fatty liver disease drugs.
BLUE: 88.80 (+0.30), ICPT: 181.90 (-8.81)
Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com
PRWeb - Tue May 05, 5:21AM CDT
The report "Liver Fibrosis - Pipeline Review, H2 2014" provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibros...eport.html .
GILD: 100.65 (-0.16), PFE: 33.24 (+0.15), GALT: 2.61 (-0.10), FGEN: 21.77 (+0.22), CELGZ: 1.74 (+0.04)
Intercept Pharmaceuticals: Serving Unmet Needs With Blockbuster Potential
DoconStocks - at Seeking Alpha - Tue Apr 28, 8:34AM CDT
GILD: 100.65 (-0.16), ICPT: 181.90 (-8.81)
Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug
at The Street - Fri Apr 24, 8:12AM CDT
None of the sugar-coated analyses presented at a meeting suggest the eventual outcome of Genfit's phase III study will be any better than the phase II study.
ICPT: 181.90 (-8.81)
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven
M2 - Mon Apr 13, 4:18AM CDT
Summary
Genfit: Refuting Bearish Arguments About Genfit's Results
Logribel Biostocks - at Seeking Alpha - Mon Apr 06, 5:58PM CDT
ICPT: 181.90 (-8.81)
Genfit Is An Even Bet To Recover In The NASH Race
Clinically Sound Investor - at Seeking Alpha - Tue Mar 31, 3:43PM CDT
RPTP: 5.99 (+0.10), GILD: 100.65 (-0.16), CNAT: 4.21 (-0.06), ICPT: 181.90 (-8.81)
Genfit: Misunderstandings And Propaganda About Phase 2b Results Provide A Good Entry Point
Logribel Biostocks - at Seeking Alpha - Tue Mar 31, 9:10AM CDT
ICPT: 181.90 (-8.81)
Genfit's French Fans Fume Following Failure of Fatty Liver Drug
at The Street - Tue Mar 31, 7:51AM CDT
French investors holding shares of Genfit are having trouble coping with the failure of the company's fatty liver disease drug GFT505.
ICPT: 181.90 (-8.81), TWTR: 30.85 (+0.53)
Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study
at The Street - Fri Mar 27, 8:40AM CDT
The GFT505 study in NASH failed, analysts said. That's bad for Genfit and good for Intercept Pharmaceuticals, which is developing a rival drug for fatty liver known as OCA.
ICPT: 181.90 (-8.81)